Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma

PDF  |  How to cite

Oncotarget. 2023; 14:668-668. https://doi.org/10.18632/oncotarget.28471

Metrics: PDF 506 views  |   ?  

Eduard Teixidor1, Elia Sais1, Carmen Amalia Vásquez2, Walter Carbajal1, Alejandro Hernández1, Gloria Sánchez3, Angel Izquierdo1, Sara Verdura4,5, Javier A. Menéndez4,5 and Joaquim Bosch-Barrera1,5,6

1Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain
2Department of Anatomical Pathology, Dr. Josep Trueta Hospital of Girona, Girona, Catalonia, Spain
3Department of Radiology, Diagnostic Imaging Institute, Doctor Josep Trueta University Hospital, Girona, Spain
4ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Catalonia, Spain
5Girona Biomedical Research Institute (IDIBGi), Girona, Catalonia, Spain
6Department of Medical Sciences, Medical School, University of Girona, Girona, Spain

Published: July 01, 2023

Copyright: © 2023 Teixidor et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Patient consent was required and obtained.

Original article: Oncotarget. 2018; 9:33043-33049. DOI: https://doi.org/10.18632/oncotarget.25984.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28471